{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:13:14Z","timestamp":1794312794493,"version":"4.9.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"DOI":"10.1186\/s12987-026-00807-4","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:49:22Z","timestamp":1776340162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of HIV and azidothymidine on Alzheimer\u2019s-like pathology and amyloid beta transporters in hu-PBL-NSG mice, brain endothelial amyloid beta uptake and endothelial barrier integrity"],"prefix":"10.1186","volume":"23","author":[{"given":"Biju","family":"Bhargavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendran","family":"Annadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgette D.","family":"Kanmogne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"807_CR1","unstructured":"Corley MJ, Chan P, Joseph SB. CROI 2025: neuropsychiatric complications in people with HIV. Top Antivir Med. 2025;33(2):483\u201393."},{"issue":"2","key":"807_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/QAD.0000000000001796","volume":"33","author":"KT Thakur","year":"2019","unstructured":"Thakur KT, et al. Global HIV neurology: a comprehensive review. AIDS. 2019;33(2):163\u201384.","journal-title":"AIDS"},{"issue":"12","key":"807_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11908-017-0606-5","volume":"19","author":"S Farhadian","year":"2017","unstructured":"Farhadian S, Patel P, Spudich S. Neurological complications of HIV infection. Curr Infect Dis Rep. 2017;19(12):50.","journal-title":"Curr Infect Dis Rep"},{"issue":"4","key":"807_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrneurol.2016.27","volume":"12","author":"D Saylor","year":"2016","unstructured":"Saylor D, et al. HIV-associated neurocognitive disorder-pathogenesis and prospects for treatment. Nat Rev Neurol. 2016;12(4):234\u201348.","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"807_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41582-023-00879-y","volume":"19","author":"RJ Ellis","year":"2023","unstructured":"Ellis RJ, et al. Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management. Nat Rev Neurol. 2023;19(11):668\u201387.","journal-title":"Nat Rev Neurol"},{"key":"807_CR6","doi-asserted-by":"crossref","unstructured":"Annadurai N, Kanmogne GD. Structural and functional Dysregulation of the brain endothelium in HIV infection and substance abuse. Cells. 2024;13(17).","DOI":"10.3390\/cells13171415"},{"key":"807_CR7","unstructured":"UNAIDS. Global HIV statistics - fact sheet 2025. 2025. https:\/\/www.unaids.org\/sites\/default\/files\/2025-07\/2025_Global_HIV_Factsheet_en.pdf."},{"issue":"1","key":"807_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/ana.410420108","volume":"42","author":"B Giometto","year":"1997","unstructured":"Giometto B, et al. Accumulation of beta-amyloid precursor protein in HIV encephalitis: relationship with neuropsychological abnormalities. Ann Neurol. 1997;42(1):34\u201340.","journal-title":"Ann Neurol"},{"issue":"1","key":"807_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/jnnp.65.1.29","volume":"65","author":"MM Esiri","year":"1998","unstructured":"Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. J Neurol, Neurosurg Psychiatry. 1998;65(1):29\u201333.","journal-title":"J Neurol, Neurosurg Psychiatry"},{"issue":"4","key":"807_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/01.aids.0000161770.06158.5c","volume":"19","author":"DA Green","year":"2005","unstructured":"Green DA, et al. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS. 2005;19(4):407\u201311.","journal-title":"AIDS"},{"issue":"2","key":"807_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s11481-009-9152-8","volume":"4","author":"CL Achim","year":"2009","unstructured":"Achim CL, et al. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol. 2009;4(2):190\u201399.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"2","key":"807_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11481-008-9143-1","volume":"4","author":"BJ Brew","year":"2009","unstructured":"Brew BJ, et al. Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol. 2009;4(2):163\u201374.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"6","key":"807_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s13365-019-00761-y","volume":"25","author":"V Soontornniyomkij","year":"2019","unstructured":"Soontornniyomkij V, et al. Associations of regional amyloid-beta plaque and phospho-tau pathology with biological factors and neuropsychological functioning among HIV-infected adults. J Neurovirol. 2019;25(6):741\u201353.","journal-title":"J Neurovirol"},{"key":"807_CR14","unstructured":"H. FDA-Approved HIV medicines. 2025. https:\/\/hivinfo.nih.gov\/understanding-hiv\/fact-sheets\/fda-approved-hiv-medicines."},{"key":"807_CR15","doi-asserted-by":"publisher","first-page":"232595822513589","DOI":"10.1177\/23259582251358929","volume":"24","author":"WS Zewdu","year":"2025","unstructured":"Zewdu WS, et al. Epidemiology of antiretroviral therapy related adverse drug reactions and its predictors among patients with human immunodeficiency Virus\/AIDS in Ethiopia: a systematic review and meta-analysis. J Int Assoc Provid AIDS Care. 2025;24:23259582251358929.","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"807_CR16","doi-asserted-by":"crossref","unstructured":"Rudd H, Toborek M. Pitfalls of antiretroviral therapy: current status and long-term CNS toxicity. Biomolecules. 2022;12(7).","DOI":"10.3390\/biom12070894"},{"issue":"7","key":"807_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41582-023-00813-2","volume":"19","author":"S Nightingale","year":"2023","unstructured":"Nightingale S, et al. Cognitive impairment in people living with HIV: consensus recommendations for a new approach. Nat Rev Neurol. 2023;19(7):424\u201333.","journal-title":"Nat Rev Neurol"},{"key":"807_CR18","unstructured":"EACS. Guidelines for the management of people living with HIV in europe. v12.0. Eur AIDS Clin Soc. 2023."},{"key":"807_CR19","unstructured":"WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. World Health Organ. 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240031593."},{"issue":"12","key":"807_CR20","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1172\/JCI10498","volume":"106","author":"M Shibata","year":"2000","unstructured":"Shibata M, et al. Clearance of Alzheimer\u2019s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 2000;106(12):1489\u201399.","journal-title":"J. Clin. Invest"},{"issue":"1","key":"807_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2174\/187152709787601867","volume":"8","author":"R Deane","year":"2009","unstructured":"Deane R, et al. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer\u2019s disease. CNS Neurol Disord Drug Targets. 2009;8(1):16\u201330.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"1","key":"807_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1172\/JCI81108","volume":"126","author":"SE Storck","year":"2016","unstructured":"Storck SE, et al. Endothelial LRP1 transports amyloid-beta(1-42) across the blood-brain barrier. J. Clin. Invest. 2016;126(1):123\u201336.","journal-title":"J. Clin. Invest"},{"issue":"4","key":"807_CR23","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1172\/JCI2029","volume":"102","author":"JB Mackic","year":"1998","unstructured":"Mackic JB, et al. Human blood-brain barrier receptors for Alzheimer\u2019s amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J. Clin. Invest. 1998;102(4):734\u201343.","journal-title":"J. Clin. Invest"},{"issue":"6","key":"807_CR24","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/hmg\/ddy017","volume":"27","author":"F Fang","year":"2018","unstructured":"Fang F, et al. RAGE mediates Abeta accumulation in a mouse model of Alzheimer\u2019s disease via modulation of beta- and gamma-secretase activity. Hum Mol Genet. 2018;27(6):1002\u201314.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"807_CR25","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2007-05-091207","volume":"111","author":"A Chaudhuri","year":"2008","unstructured":"Chaudhuri A, et al. STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood. 2008;111(4):2062\u201372.","journal-title":"Blood"},{"issue":"1","key":"807_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13024-021-00500-0","volume":"16","author":"B Bhargavan","year":"2021","unstructured":"Bhargavan B, et al. CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice. Mol Neurodegener. 2021;16(1):78.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"807_CR27","doi-asserted-by":"publisher","first-page":"10689","DOI":"10.1038\/s41598-019-47069-9","volume":"9","author":"B Bhargavan","year":"2019","unstructured":"Bhargavan B, Kanmogne GD. Epigenetics, N-myrystoyltransferase-1 and casein kinase-2-alpha modulates the increased replication of HIV-1 CRF02_AG, compared to subtype-B viruses. Sci Rep. 2019;9(1):10689.","journal-title":"Sci Rep"},{"issue":"1","key":"807_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1164\/rccm.201106-1151OC","volume":"190","author":"H Li","year":"2014","unstructured":"Li H, et al. Dysregulation of claudin-5 in HIV-induced interstitial pneumonitis and lung vascular injury. Protective role of peroxisome proliferator-activated receptor-gamma. Am J Respir Crit Care Med. 2014;190(1):85\u201397.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"807_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27\u201331.","journal-title":"J Basic Clin Pharm"},{"issue":"3","key":"807_CR30","first-page":"1","volume":"31","author":"J-W Shin","year":"2010","unstructured":"Shin J-W, Seol I-C, Son C-G. Interpretation of animal dose and human equivalent dose for drug development. J Sport Hist Korean Orient Med. 2010;31(3):1\u20137.","journal-title":"J Sport Hist Korean Orient Med"},{"key":"807_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1742-4690-11-20","volume":"11","author":"SM Woollard","year":"2014","unstructured":"Woollard SM, et al. HIV-1 induces cytoskeletal alterations and Rac1 activation during monocyte-blood-brain barrier interactions: modulatory role of CCR5. Retrovirology. 2014;11:20.","journal-title":"Retrovirology"},{"issue":"2","key":"807_CR32","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1007\/s12035-017-0382-0","volume":"55","author":"B Bhargavan","year":"2018","unstructured":"Bhargavan B, Kanmogne GD. Differential Mechanisms of inflammation and endothelial dysfunction by HIV-1 subtype-B and Recombinant CRF02_AG Tat proteins on human brain microvascular endothelial cells: implications for viral neuropathogenesis. Mol Neurobiol. 2018;55(2):1352\u201363.","journal-title":"Mol Neurobiol"},{"issue":"4","key":"807_CR33","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1172\/JCI58642","volume":"122","author":"R Deane","year":"2012","unstructured":"Deane R, et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Invest. 2012;122(4):1377\u201392.","journal-title":"J. Clin. Invest"},{"issue":"7","key":"807_CR34","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1128\/AAC.44.7.1900-1905.2000","volume":"44","author":"S Francke","year":"2000","unstructured":"Francke S, et al. Effect of zidovudine on the primary cytolytic T-lymphocyte response and T-cell effector function. Antimicrob Agents Chemother. 2000;44(7):1900\u201305.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"807_CR35","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1128\/AAC.01632-15","volume":"60","author":"AB Sanchez","year":"2016","unstructured":"Sanchez AB, et al. Antiretrovirals, methamphetamine, and HIV-1 envelope protein gp120 compromise neuronal energy homeostasis in association with various degrees of synaptic and neuritic damage. Antimicrob Agents Chemother. 2016;60(1):168\u201379.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"807_CR36","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.bbadis.2016.11.017","volume":"1863","author":"KM Hung","year":"2017","unstructured":"Hung KM, et al. Mitochondrial defects arise from nucleoside\/nucleotide reverse transcriptase inhibitors in neurons: potential contribution to HIV-associated neurocognitive disorders. Biochim Biophys Acta Mol Basis Dis. 2017;1863(2):406\u201313.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"21","key":"807_CR37","doi-asserted-by":"publisher","first-page":"18736","DOI":"10.1074\/jbc.M201979200","volume":"277","author":"P May","year":"2002","unstructured":"May P, Reddy YK, Herz J. Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. J Biol Chem. 2002;277(21):18736\u201343.","journal-title":"J Biol Chem"},{"issue":"51","key":"807_CR38","doi-asserted-by":"publisher","first-page":"35507","DOI":"10.1074\/jbc.M806948200","volume":"283","author":"L Zhang","year":"2008","unstructured":"Zhang L, et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem. 2008;283(51):35507\u201316.","journal-title":"J Biol Chem"},{"issue":"10","key":"807_CR39","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1096\/fj.08-109033","volume":"22","author":"A Raucci","year":"2008","unstructured":"Raucci A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). Faseb J. 2008;22(10):3716\u201327.","journal-title":"Faseb J"},{"key":"807_CR40","unstructured":"UNAIDS. World Health Organization (WHO) 2022 organizational report. 2023. https:\/\/open.unaids.org\/sites\/default\/files\/documents\/10.%202022%20WHO.pdf. UNAIDS.ORG."},{"key":"807_CR41","unstructured":"Paton NI, et al. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. Lancet HIV. 2022;9(6):e381\u201393."},{"issue":"4","key":"807_CR42","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa2101609","volume":"385","author":"NI Paton","year":"2021","unstructured":"Paton NI, et al. Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV. N Engl J Med. 2021;385(4):330\u201341.","journal-title":"N Engl J Med"},{"issue":"10","key":"807_CR43","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40262-014-0171-0","volume":"53","author":"A Calcagno","year":"2014","unstructured":"Calcagno A, Perri GD, Bonora S. Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. Clin Pharmacokinet. 2014;53(10):891\u2013906.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"807_CR44","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tins.2020.06.007","volume":"43","author":"O Osborne","year":"2020","unstructured":"Osborne O, et al. The paradox of HIV blood-brain barrier penetrance and antiretroviral drug delivery deficiencies. Trends Neurosci. 2020;43(9):695\u2013708.","journal-title":"Trends Neurosci"},{"issue":"3","key":"807_CR45","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4103\/ijp.IJP_304_16","volume":"49","author":"S Mukherjee","year":"2017","unstructured":"Mukherjee S, et al. Adverse drug reaction monitoring in patients on antiretroviral therapy in a tertiary care hospital in Eastern India. Indian J Pharmacol. 2017;49(3):223\u201328.","journal-title":"Indian J Pharmacol"},{"issue":"18","key":"807_CR46","doi-asserted-by":"publisher","first-page":"15666","DOI":"10.1074\/jbc.M200887200","volume":"277","author":"P Kienlen-Campard","year":"2002","unstructured":"Kienlen-Campard P, et al. Intracellular amyloid-beta 1-42, but not extracellular soluble amyloid-beta peptides, induces neuronal apoptosis. J Biol Chem. 2002;277(18):15666\u201370.","journal-title":"J Biol Chem"},{"issue":"7","key":"807_CR47","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrn2168","volume":"8","author":"FM LaFerla","year":"2007","unstructured":"LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer\u2019s disease. Nat. Rev. Neurosci. 2007;8(7):499\u2013509.","journal-title":"Nat. Rev. Neurosci"},{"key":"807_CR48","first-page":"8","volume":"2","author":"TA Bayer","year":"2010","unstructured":"Bayer TA, Wirths O. Intracellular accumulation of amyloid-beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer\u2019s disease. Front Aging Neurosci. 2010;2:8.","journal-title":"Front Aging Neurosci"},{"issue":"21","key":"807_CR49","doi-asserted-by":"publisher","first-page":"11466","DOI":"10.1073\/pnas.97.21.11466","volume":"97","author":"H Xiao","year":"2000","unstructured":"Xiao H, et al. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci U S A. 2000;97(21):11466\u201371.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"807_CR50","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/sj.jcbfm.9600254","volume":"26","author":"K Hayashi","year":"2006","unstructured":"Hayashi K, et al. HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier. J Cereb Blood Flow Metab. 2006;26(8):1052\u201365.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"33","key":"807_CR51","doi-asserted-by":"publisher","first-page":"13588","DOI":"10.1073\/pnas.1308673110","volume":"110","author":"TP Johnson","year":"2013","unstructured":"Johnson TP, et al. Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A. 2013;110(33):13588\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"807_CR52","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00401-006-0115-3","volume":"112","author":"JE Donahue","year":"2006","unstructured":"Donahue JE, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer\u2019s disease. Acta Neuropathol. 2006;112(4):405\u201315.","journal-title":"Acta Neuropathol"},{"issue":"9","key":"807_CR53","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1172\/JCI11013","volume":"106","author":"DE Kang","year":"2000","unstructured":"Kang DE, et al. Modulation of amyloid beta-protein clearance and Alzheimer\u2019s disease susceptibility by the LDL receptor-related protein pathway. J. Clin. Invest. 2000;106(9):1159\u201366.","journal-title":"J. Clin. Invest"},{"issue":"2","key":"807_CR54","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/ana.410370212","volume":"37","author":"GW Rebeck","year":"1995","unstructured":"Rebeck GW, et al. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor\/low-density-lipoprotein receptor-related protein. Ann Neurol. 1995;37(2):211\u201317.","journal-title":"Ann Neurol"},{"key":"807_CR55","doi-asserted-by":"crossref","unstructured":"Miller MC, et al. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer\u2019s disease. Brain Res, 2008. 1230;273\u201380.","DOI":"10.1016\/j.brainres.2008.06.124"},{"issue":"47","key":"807_CR56","doi-asserted-by":"publisher","first-page":"20021","DOI":"10.1073\/pnas.0905686106","volume":"106","author":"K Takuma","year":"2009","unstructured":"Takuma K, et al. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci U S A. 2009;106(47):20021\u201326.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"807_CR57","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1074\/jbc.M117.786756","volume":"293","author":"J Gasparotto","year":"2018","unstructured":"Gasparotto J, et al. Receptor for advanced glycation end products mediates sepsis-triggered amyloid-beta accumulation, Tau phosphorylation, and cognitive impairment. J Biol Chem. 2018;293(1):226\u201344.","journal-title":"J Biol Chem"},{"issue":"5","key":"807_CR58","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.neurobiolaging.2009.04.016","volume":"32","author":"V Srikanth","year":"2011","unstructured":"Srikanth V, et al. Advanced glycation endproducts and their receptor RAGE in Alzheimer\u2019s disease. Neurobiol Aging. 2011;32(5):763\u201377.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"807_CR59","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pharmthera.2012.07.008","volume":"136","author":"AP Sagare","year":"2012","unstructured":"Sagare AP, Deane R, Zlokovic BV. Low-density lipoprotein receptor-related protein 1: a physiological Abeta homeostatic mechanism with multiple therapeutic opportunities. Pharmacol Ther. 2012;136(1):94\u2013105.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"807_CR60","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1096\/fj.07-9909com","volume":"22","author":"BI Hudson","year":"2008","unstructured":"Hudson BI, et al. Identification, classification, and expression of RAGE gene splice variants. Faseb J. 2008;22(5):1572\u201380.","journal-title":"Faseb J"},{"key":"807_CR61","doi-asserted-by":"publisher","first-page":"101958","DOI":"10.1016\/j.redox.2021.101958","volume":"42","author":"JD Erusalimsky","year":"2021","unstructured":"Erusalimsky JD. The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes. Redox Biol. 2021;42:101958.","journal-title":"Redox Biol"},{"issue":"1\u20132","key":"807_CR62","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.bbadis.2005.03.014","volume":"1741","author":"MO Chaney","year":"2005","unstructured":"Chaney MO, et al. RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim Biophys Acta. 2005;1741(1\u20132):199\u2013205.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"807_CR63","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3233\/JAD-170639","volume":"61","author":"CD Pereira","year":"2018","unstructured":"Pereira CD, et al. ABC transporters are key players in Alzheimer\u2019s disease. J Alzheimers Dis. 2018;61(2):463\u201385.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"807_CR64","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1007\/s12035-020-02211-x","volume":"58","author":"T Behl","year":"2021","unstructured":"Behl T, et al. The interplay of ABC transporters in Abeta translocation and cholesterol metabolism: implicating their roles in Alzheimer\u2019s disease. Mol Neurobiol. 2021;58(4):1564\u201382.","journal-title":"Mol Neurobiol"},{"issue":"4","key":"807_CR65","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/135965350400900403","volume":"9","author":"S Jorajuria","year":"2004","unstructured":"Jorajuria S, et al. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther. 2004;9(4):519\u201328.","journal-title":"Antivir Ther"},{"key":"807_CR66","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.lfs.2015.10.025","volume":"152","author":"S Dutta","year":"2016","unstructured":"Dutta S, Sengupta P. Men and mice: relating their ages. Life Sci. 2016;152:244\u201348.","journal-title":"Life Sci"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-026-00807-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-026-00807-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-026-00807-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:21:09Z","timestamp":1779769269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12987-026-00807-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1186\/s12987-026-00807-4","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}